1. Home
  2. |Insights
  3. |C5 - 3rd EU Pharma Law & Regulation Conference

C5 - 3rd EU Pharma Law & Regulation Conference

Event

2012 is set to be a critical year for EU pharma regulation with the implementation of the pharmacovigilance rules, proposals to amend the data protection and clinical trials directives and the new falsified medicinal products directive.


In addition, the Mediator case triggered an overhaul of regulation governing the healthcare sector in France and a drive towards increased transparency and the impact of this case is likely to be felt across the EU.


Questions are being raised about anti-corruption efforts and where we are a year on from the introduction of the UK Bribery Act.


There are a number of competition law developments, there are concerns regarding off-label promotion and a number of legal problems are arising as a result of pharma companies developing their social media presence.


The budgetary pressures across Europe and the Eurocrisis are having a critical impact on health authorities across Europe and the scope of SPCs has been clarified.


Werner Berg is speaking on the topic, "How to Align Your Business Practices in Light of Recent Competition Law Judgments."

Attachments

Insights

Event | 02.20.25

Has the Buss Stopped? Recoupment Today

Has the Buss Stopped? Recoupment Today: In 1997, the California Supreme Court decided Buss v. Superior Court. In Buss, the court concluded that a liability insurer that defended a mixed action could seek reimbursement from the insured for the defense costs associated with the claims that were not even potentially covered. Since then, numerous courts have held that insurers are entitled to recoup their defense costs associated with uncovered claims or causes of action. On the other hand, a significant number of courts have rejected insurers’ right to recoupment, at least in the absence of a policy provision granting the insurer that right. Some commentators have even suggested that the current judicial trend might be away from permitting insurers to recoup their defense costs. Is that correct? Has the Buss stopped? This panel of coverage experts will analyze insurers’ claimed right to recoupment today, and offer their perspectives on what the law on recoupment should perhaps be and might be in the future.

View All Insights